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Abstract 
Tuberculosis diagnosis and monitoring rely in Sputum microscopy of National Tuberculosis Programme, Nepal 
because of its low cost and easier to perform. Direct sputum microscopy is popular worldwide. Currently, there 
are 533 microscopy centres catering for sputum microscopy examination throughout the country. Most of the 
microscopy centres are established within government jurisdiction and remaining are established as non-
governmental organization as well as private sectors.  
A cross-sectional study was conducted from July 2013 to January 2015. A total of 2091 patients were enrolled in 
the study who were attending the DOTS Centre in Parsa District of Public Health Office, Nepal. Smears stained 
with ZN stain methods were examined microscopically followed by the GeneXpert MTB/RIF assay.  
Out of 2091 suspected pulmonary TB patients enrolled for sputum microscopy and GeneXpert MTB/RIF for the 
confirmation of TB, the 1301(62.21%) were male and 790 (37.78%) were female. The maximum TB cases were 
from Parsa district (555, 26.5%). The comparative study of different diagnostic tools reveals the sensitivity of 
MTB/RIF was 95.50% (91.87, 97.82) and significantly higher than smear microscopy performed on the same fluid, 
which had a sensitivity of 61.97% (55.41, 68.21). Five of 127 smear-negative cases had MTB/RIF-positive un-
centrifuged sputum, resulting in a specificity of 81.23% (75.95, 85.78), which was similar to smear microscopy 
98.29 % (97.34, 98.97; p=0.121). The positive predictive value (PPV) and negative predictive value (NPV) of 
MTB/RIF were 96.85% (93.61, 98.72) and 94.95 % (93.52, 96.14), respectively. HIV co-infection did not impact 
sensitivity, specificity or liquid culture time to positivity (TTP). When MTB/RIF accuracy was evaluated using 
composite reference standard culture positivity from sputum, the sensitivity and specificity were similar to those 
obtained in the primary analysis using either definite TB versus possible and non-TB combined; definite and 
possible TB combined versus non-TB.  
Keywords: Mycobacterium tuberculosis, Prevalence, GeneXpert, Nepal 
*Corresponding Authors  
E-mail: dr_roshankurmi@hotmail.com   
Introduction 
Tuberculosis (TB) is a leading cause of death 
worldwide. In the early 1990s, the government of 
Nepal brought up a program to control TB at 
national scale called DOTS (Directly Observed 
Treatment Short Course) [1]. DOTS program was 
initiated in April 2001 with a goal to diagnose and 
cure TB patients which has treated more than 20  
thousand patients till date [2]. Until December of 
2014 there are 554 microscopy centres and 22 
GenXpert location in the country which specializes 
in diagnosis of TB [3]. The expansion of DOTS 
program has proven its efficacy in reducing the 
mortality and morbidity in Nepal, however, 
despite of available diagnosis and treatment 
regimes, approximately 3000-5000 people are still 
dying per year  of TB [4]. In a DOTS centre in 
Kathmandu, prevalence of Multi Drug Resistant 
(MDR) case of Tuberculosis was found to be 3.6% 
[5], which could have been mitigated by early 
diagnosis and rapid identification of anti-TB agents 
resistance. Recent data from East Nepal suggests 
that 3.3% of all patients, who were smear 
microscopy negative, have RMP resistant TB [6]. 
Despite of DOTS and available diagnosis, 
complications due to MDR are emerging and also 
there hasn’t been overall increment in number of 
people on anti tuberculosis treatment [6]. Sputum 
smear light microscopy, patients symptoms 
combined with CXR results is the preferred 
algorithm for TB diagnosis in Nepal.  Smear test is 
neither relevant nor sensitive enough for the 
diagnosis of TB alone and needs additional 
diagnosis as well clinical suspecting to decide 
either patients should be enrolled on antibiotic or 
not [7].  
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This study aims to clarify if current algorithm of TB 
diagnosis is flexible enough to trace the TB rates at 
GeneXpert centre in Parsa district of Public Health 
Office, Nepal. Our aims were to determine 
epidemiological characteristics, HIV status of 
patients with tuberculosis and comparative study 
of different test routinely used for diagnosis of TB 
at a large outpatient clinic in Parsa of Nepal.  
Materials and Methods 
Study sites and population 
Study was conducted in Parsa district in the 
Narayani Zone of southern Nepal which lies 
283 km (176 mi) south of the capital Kathmandu, 
3 km north of the border of the Indian state of Bihar 
with population 315,011 in 2011. The district is 
divided into 86 Village Development Committees 
and one municipality which is one of the relatively 
well developed districts in the country located on 
the flat Terai lowland. The public health sector has 
49 facilities including 1 zonal hospital, 1 public 
health office, 3 primary health centres, 9 health 
posts and 35 sub-health posts, additionally there 
are 6 private sector facilities thus resulting in a total 
of 55 facilities providing DOTS services in Parsa 
district. The reported notification rate of new 
pulmonary positive tuberculosis in Parsa district 
was 69 per 100,000 populations in 2014 [3].  
Patient classification and diagnosis 
algorithm  
Patients with suspected TB (≥18 ye of age) were 
enrolled between April 2014 and May 2015. WHO 
algorithm was basis for the classification of 
suspects of TB. Based on WHO algorithm, two 
subgroups were formed to classify TB suspects; 1) 
patients with cough for ≥ 2 weeks and 2) patients 
without cough for ≥ 2 weeks but having symptoms 
like weight loss accompanied with night fever 
T>37.5°C, pleural effusion or pericarditis induced 
breathlessness, chronic headache, swelled armpit 
(>2cm) or abnormal chest radiogram, thus referred 
as, “with cough or without cough’’. Patients with 
WHO defined danger sign with respiratory rate  
>30/minute, fever >39°C, pulse rate >120/minute 
and unambulatory patients were excluded from the 
study.  
Smear positive were not enrolled for GenXpert thus 
were directly enrolled for anti TB regime. 
Remaining patients with smear negative were 
enrolled in GenXpert and further confirmation was 
done by liquid culture for MTB positive and RIF 
resistant samples. Those cultures were further 
screened for MDR against first line and second line 
drugs.  
Patients with sputum negative for TB were 
classified as possible TB (if they are on anti-TB 
treatment program) or as non-TB (if they are not on 
anti-TB treatment program). Prospective patients 
(≥20 years of age) with suspected pulmonary TB 
(n=2091) were enrolled in the study who were 
attending the DOTS Centre in Parsa District of 
Public Health Office, Nepal from Jul 2013 to Jan 
2015. Patients had at least one symptom of TB 
including chest radiograph with infiltrates and 
smear microscopy negative results in duplicate.   
Specimen collection and laboratory 
procedures 
Sputum specimens were processed using 
standardized protocols. The length of time between 
sample collection and results being issued to the 
clinic was also recorded. Smears stained with ZN 
stain methods were examined microscopically 
following the standard protocol. At least 200 fields 
were evaluated before reporting  negative. Bacillary 
density was graded as scanty, 1+, 2+, and 3+, and 
all such smears were defined as ‘‘smear-positive’. 
Following decontamination with N-acetyl-L-
cysteine and sodium hydroxide, centrifuged 
sputum deposits underwent microscopy, and 
following re-suspension in phosphate buffer, equal 
volumes were tested by the GeneXpert MTB/RIF 
assay. The results of all tests were read by 
technologists blinded to the outcomes of the other 
assays. Sputum pellets were also tested by trained 
technologists using the GeneXpert MTB/RIF assay.  
 GeneXpert MTB/RIF and patient 
management 
The collected sputum sample was aliquoted in two 
equal volumes; first half for immediate primary 
clinical works and other for reference for future 
works at -20°C. From the first aliquot, the specimen 
was used for smear tests followed by GeneXpert 
MTB/RIF assay. The diagnostic assays were 
followed by a single specialized clinical research 
associate blind to the patient's diagnosis in 
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reference standard and index test, throughout the 
study period. 
Statistical analysis 
Collected data were analyzed and interpreted 
statistically using graphPad prism version 6.0 and 
SPSS 17.0. All the values are expressed as mean±SD 
and are analyzed using Student’s t test which is 
parametric as well Mann-Whitney test wherever 
applicable. P value (P<0.05), was considered 
significant unless stated otherwise.  
Results 
Study population and TB diagnoses 
Figure 1: District wise number of Tuberculosis Patients 
visited at GeneXpert Centre in Parsa  
The suspected pulmonary TB patients (n= 2091) 
were enrolled for sputum microscopy and 
GeneXpert MTB/RIF for the confirmation of TB. 
Among them, 1301(62.21%) were male and 790 
(37.78%) were female. All the patients were 
referred to this centre by local doctors and 
physicians after having tuberculosis symptoms and 
abnormal chest radiograph for sputum microscopy 
and GeneXpert MTB/RIF for the confirmation of 
Makwanpur, Mahottari, Panchthar, Saptari, Siraha, 
Morang, Sindhuli, Rasuwa and Chitwan (Figure 1). 
Since the study conducted at Parsa district, the 
actual number of case presented here does not 
highlight the prevalence of TB in the respective 
district.  
 As Bara is the adjacent district to Parsa, the 
number of patients visited is more than other 
district. The prevalence of TB in Parsa district is 3 
times higher than the prevalence in the Bara 
district. 
 TB. The clinical symptoms showed most of the 
patients have fever, cough, and weight loss and 
night sweat (Table 4). 
The maximum TB cases were from Parsa district 
(555, 26.5%) followed by Bara, Rautahat, Sarlahi,  
Diagnostic accuracy of different method 
and MTB/RIF performed on un-
centrifuged sputum 
Direct sputum microscopy is popular worldwide. 
In Nepal, the Tuberculosis diagnosis and 
monitoring rely in Sputum microscopy because of 
its low cost and easier to perform. At present there 
are 533 microscopy centres catering the sputum 
microscopy examination throughout the country. 
The region wise distribution is given in Table 1. 
Most of the microscopy centres are established in 
government setting and few are established in non-
governmental organization and private sectors.  
NTC-National  
 
Figure 2: MDR Pattern in TB Patients  
Figure 3: Gene Xpert MTB RIF Pattern in TB patient 
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Table 4: Clinical Feature of Tuberculosis 
Clinical Feature Present Absent 
Fever 1885 206 
Cough 1741 350 
Weight Loss 1471 620 
Night sweat 1655 436 
Loss of appetite 1376 715 
Malaise 1117 974 
Chest Pain 1744 347 
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Reference Laboratory and GENETUP are providing 
culture and in the beginning of 2012, a new 
molecular diagnostic tool; Gene Xpert MTB/RIF 
machines for rapid diagnosis of DR TB had been 
introduced to nine health facilities (7 in Eastern 
Region and 2 in Central Region) in collaboration 
with NTP Nepal and International Organization for 
Migration (IOM) through TB Reach funding. Gene 
Xpert MTB RIF Pattern in TB patient and MDR 
Pattern in TB Patients are shown in Figure 2 and 
Figure 3 respectively. 
Table 1: Number of DOTS and Microscopy Centres by 
Region 
Development 
Region/ 
Centres 
EDR CDR WD
R 
MWD
R 
FW
DR 
Total 
No. of 
treatment 
centres 
237 366 239 199 143 1184 
No. of Sub-
centres 
709 1008 667 406 284 3074 
DR TB 
Treatment 
centres 
2 4 3 1 3 13 
DR TB 
Treatment 
sub-centres 
11 37 15 5 3 71 
Microscopy 
centres 
122 198 82 73 79 554 
* Showed the number of DOTS and Microscopy centres in which 
number of sub-centres are more followed by number of 
treatment centres and microscopy centres. There is few DR TB 
treatment centres. (EDR: Eastern Development Region. CDR: 
Central Development Region; WDR: Western Development 
Region; MWDR: Mid Western Development Region; FWDR: Far 
Western Development Region) 
Table 3:  Comparison of different test for diagnosis of 
pulmonary Tuberculosis 
Test Result 
Smear Positive 585 
Smear Negative 1506 
Gene Xpert Positive 788 
Gene Xpert Negative 1303 
 
The comparative study of different diagnostic tools 
is given in Table 3.  
Of the 2091 patients enrolled in this study, the 
sensitivity of MTB/RIF was 95.50% (91.87, 97.82) 
and significantly higher than smear microscopy 
performed on the same fluid, which had a 
sensitivity of 61.97% (55.41, 68.21, Table 5). Five of 
127 smear-negative cases had MTB/RIF-positive 
un-centrifuged sputum, resulting in a specificity of 
81.23% (75.95, 85.78), which was similar to smear 
microscopy 98.29 % (97.34, 98.97; p=0.121). The 
positive predictive value (PPV) and negative 
predictive value (NPV) of MTB/RIF were 96.85% 
(93.61, 98.72) and 94.95 % (93.52, 96.14), 
respectively. HIV co-infection did not impact 
sensitivity, specificity (Table 6) or TTP. When 
MTB/RIF accuracy was evaluated using composite 
reference standard culture positivity from sputum, 
the sensitivity and specificity were similar to those 
obtained in the primary analysis using either 
definite TB versus possible and non-TB combined; 
definite and possible TB combined versus non-TB.  
Discussion 
In Nepal, the estimated incidence of TB is 163 per 
100,000 with a prevalence rate of 241 per 100,000 
populations. In 2014-15, the Nepal Tuberculosis 
Programme (NTP) registered 17,788 sputum smear-
positive cases and 8,367 sputum smear negative 
cases [6, 8]. A total of 2091 individuals from 
thirteen districts of Nepal were included in the 
present study and the prevalence of smear positive 
pulmonary tuberculosis was found to be 788 out of 
2091(37.06 %). We found the most of the patients 
were passively participated in the study and almost 
all patients are visited Government hospital for the 
treatment. Approximately 66.76% of the patient 
had the cough duration for last 2 days. Although, 
only 37.09 % of patients had AFB positive on 
smear, out of which 97.8 % were new  
Table 5: Pattern of sputum culture with active TB 
Parameters  
Cohort 
(n=2091) 
Sputum smear 
positive with 
active TB 
(n=672) 
Sputum smear 
negative 
compatible with 
active TB 
(n=1419) 
Median age in 
years 
37.3 (26.1-
48.3) 
33.8 (28.1-
42.8) 
37.4 (29.9-47.1) 
Male 1301 464 725 
Female 790 208 694 
HIV infected 65 22 43 
Median CD4 
counts (If HIV 
positive) 
98 78 20 
Previous TB 
treatment 
89 9 80 
Smokers (Past 
or current) 
201 118 83 
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cases and only 2.2. % is repeated cases; the Chest X 
ray reveals 99.43% had abnormal finding in chest. 
The GeneXpert result shows large number of 
patients diagnosed with Tuberculosis.  This might 
be that the AFB is not present in initial few days 
because most of the patient has visited less than 5 
days of appearance of cough. The similar study 
carried by Shagufta Iram et al[9], shows the 
GeneXpert MTB/RIF is a sensitive method for 
rapid diagnosis of Tuberculosis, especially in smear 
negative cases and in PTB as compared to the 
conventional ZN staining. For countries endemic 
for TB GeneXpert can serve as a sensitive and time 
saving diagnostic modality for pulmonary TB. Our 
study is consistent with other studies which have 
suggested the benefit of GeneXpert in smear-
negative patients in developing countries [10, 
11].The majority of these studies have been carried 
out in Africa where there is a substantially higher 
HIV burden than in South Asia. Three studies have 
been reported from low-HIV prevalence regions, 
including Peru and two hospitals (Hinduja 
Hospital and Christian Medical College Hospital) 
in India [11, 12].   
It is not clear how many of the patients testing 
positive for MTB by smear, culture and Gene Xpert 
in this study would have been started on TB 
treatment based on the judgement of the treating 
clinician if GeneXpert testing was not available. In 
the previous year (2013-2014) at Parsa district, 2245 
patients were treated for TB, approximately one-
third of those detected by GeneXpert during the 
study period. It is possible that the availability of 
GeneXpert increased the recognition of TB 
symptoms, although we can claim that in this 
endemic setting TB awareness is consistently high 
among clinicians. Conversely, it is possible that a 
negative smear test may have discouraged 
Table 6: Accuracy of Xpert  MTB/RIF for the detection of Smear positive TB in sputum 
 All patients 
n=2091 
 HIV uninfected 
n=2026 
 HIV infected 
n=65 
 
 Sensitivity, % 
(95% CI) 
Specificity, % 
(95% CI) 
Sensitivity, % 
(95% CI) 
Specificity, % 
(95% CI) 
Sensitivity, % 
(95% CI) 
Specificity, 
% (95% CI) 
Smear microscopy 61.97% 
(55.41,68.21) 
96.48 % (95.24, 
97.48) 
78.38% 
(71.74, 84.08) 
92.50 % 
(90.85,93.93) 
62.36% 
(51.93,64.82) 
95.23 % 
(93.84, 97.41) 
MTB/RIF 
performed on 
uncentrifuged 
sputum 
95.50% 
(91.87, 97.82) 
94.69 % 
(93.23, 95.92) 
77.66% 
(72.24, 82.46) 
 
99.09 % 
(98.33, 99.56) 
 
94.13% 
(90.16, 95.28) 
92.47 % 
(90.67, 94.54) 
MTB/RIF 
performed on 
uncentrifuged 
sputum in patients 
who were smear 
negative 
81.23% 
(75.95, 85.78) 
98.29 % 
(97.34, 98.97) 
91.77% 
(87.45, 94.98) 
95.70 % 
(94.36, 96.80) 
83.82% 
(76.72, 86.26) 
94.78 % 
(91.23, 97.76) 
MTB/RIF 
performed on a 
resuspended pellet 
of centrifuged 
sputum 
51.89% 
(44.94,58.78) 
93.79 % 
(92.24, 95.11) 
60.44% 
(52.94, 67.60) 
91.42 % 
(89.68, 92.95) 
52.62% 
(46.73, 56.28) 
91.72% 
(89.91, 93.63) 
 PPV† 
(95% CI) 
NPV† 
(95% CI) 
PPV† 
(95% CI) 
NPV† 
(95% CI) 
PPV† 
(95% CI) 
NPV† 
(95% CI) 
Smear microscopy 47.44% 
(40.61,54.34) 
92.73 % 
(91.08, 94.16) 
54.84 % 
(47.39, 62.13) 
90.46 % 
(88.65, 92.08) 
85.95% 
(80.92, 90.07) 
98.76 % 
(97.93, 99.32) 
MTB/RIF 
performed on 
uncentrifuged 
sputum 
96.85% 
(93.61,98.72) 
 
94.95 % 
(93.52, 96.14) 
78.75% 
(73.42, 83.45) 
99.36 % 
(98.69,99.74) 
93.69% 
(89.65, 96.51) 
97.04 % 
(95.89,97.94) 
MTB/RIF 
performed on 
uncentrifuged 
sputum in patients 
who were smear 
negative 
62.61% 
(56.12,68.77) 
97.09 % 
(95.93, 97.99) 
81.87% 
(75.49, 87.18) 
92.51 % 
(90.87, 93.95) 
51.89% 
(44.94, 58.78) 
94.48 % 
(93.00, 95.72) 
MTB/RIF 
performed on a 
resuspended pellet 
of centrifuged 
sputum 
47.44% 
(40.61,54.34) 
92.73% 
(91.08, 94.16) 
54.84% 
(47.39, 62.13) 
90.46 % 
(88.65, 92.08) 
90.13% 
(87.25,92.47) 
52.43% 
(49.10, 53.91) 
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treatment in some cases which would otherwise 
have been treated, although clinicians were 
informed that a negative smear test does not 
exclude a TB diagnosis. Patients with a strong 
possibility of pulmonary TB despite a negative 
smear test were referred for further investigations 
including culture at a tertiary centre. The rate of 
smear positivity at Parsa is 15.0 % which is 
consistent with the results in other areas of similar 
endemicity; it is therefore unlikely that the 
GeneXpert diagnosis was inflated due to low smear 
microscopy confirmation [13-15].  
If we look on test selection, smear microscopy, due 
to its simplicity, speed, and low cost, is used widely 
in low-resource settings; the low sensitivity 
precludes it from being an ideal test. The 
requirement for a rapid, simple TB diagnostic is 
evidenced by the widespread application of 
commercial serological tests which are inaccurate. 
These tests are widely provided at a cost to the 
patient and used to determine medical treatment.  
Although the GeneXpert has several limitations, 
including requirement for stable electricity supply, 
limited temperature range, availability of 
maintenance, and bulky consumables, wider 
availability of the accurate GeneXpert assay may 
counter the use of these serological tests by 
providing a viable alternative to the patient and 
healthcare provider. It is highly probable that a 
small number of cases of TB were missed in this 
study as GeneXpert does not have as high 
sensitivity as culture. There is a danger that 
clinicians will “exclude” a TB diagnosis on the 
basis of a negative GeneXpert test and it is 
important that education is carried out to ensure 
clinicians are aware of the test limitations prior to 
the test being implemented. However, it is not 
sustainable to implement TB culture facilities at 
general hospitals in South Asia and the long 
turnaround of results means loss to follow-up in 
the diagnostic pathway is high. This study was not 
an assessment of GeneXpert sensitivity and 
specificity, as this has been comprehensively 
evaluated in comparison with culture by others. 
Conclusion  
The prevalence of TB is high in Parsa DOTS centre 
in comparable to other districts of Nepal. However, 
the relatively higher rate of RIF resistance observed 
in our study signals the danger of increasing 
MDRTB in the study areas in the future in Nepal. 
On the other hand, MTB RIF positivity among 
sputum negative, RIF resistant (DR TB) among 
sputum negative and RIF resistant among 
retreatment cases is large in this study. The higher 
level of MDR-TB among previously treated patients 
suggests the need to strengthen the DOTS strategy 
and the capacity of laboratories to undertake 
effective treatment especially among previously 
treated patients in Nepal. The GeneXpet is more 
specific and sensitive that smear AFB detection. 
The Government of Nepal Ministry of Health and 
population should implement GeneXpert in each 
DOTS centre in Nepal for better diagnosis. 
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